On Air Now

Current Show

The Rush Limbaugh Show   11:00 AM - 2:00 PM

Call The Rush Limbaugh Show at 1-800-282-2882.

Show Info »

Upcoming Shows

Program Schedule »


Listen Live Now » 550 AM Wausau, WI 99.9 FM Stevens Point, WI


Current Conditions(Wausau,WI 54403)

More Weather »
63° Feels Like: 63°
Wind: W 17 mph Past 24 hrs - Precip: 0”
Current Radar for Zip


Sunny 65°


Clear 44°


Sunny 72°


Breaking News

BREAKING NEWS: Wausau PD to discuss "the recovery of Stephanie Low's body" at news conference today

WAUSAU, Wis (WSAU)  Wausau police say Stephanie Low's body has been found. A news release from Police Chief Jeff Hardell says that they will hold a news conference at 4pm this afternoon to discuss "the recovery of Stephanie Low's body". Further details are not immediately available. Low was 22-years-old when she disappeared in 2010. Police have since treated the case as a homicide. Until now her body has never been found, and no one has ever been charged in her death or disappearance. P...

Read More »

Clovis shares double on positive early data for lung cancer drug

(Reuters) - Clovis Oncology said initial results of an early-stage trial of its experimental lung cancer drug showed a reduction in tumor size, prompting investors to more than double the company's market value on Monday.

The experimental therapy, named CO-1686, aims to treat non-small-cell lung cancer (NSCLC) in patients with a mutation in gene T790M.

"(The) data was extremely impressive and we believe further highlights the drug's paradigm changing potential for at least refractory NSCLC patients with (this) mutation," Leerink Swann analyst Marko Kozul wrote in a note.

Shares of Clovis, which had a market capitalization of about $960 million as on Friday, touched a life high of $86.29 before paring some gains to trade up 127 percent at $83.20. The stock was the top percentage gainer on the Nasdaq on Monday.

Forty-two patients were treated with CO-1686 as of May 2013, and the company highlighted initial findings of the treatment on six patients.

Clovis said four of the six patients showed partial response to the disease, while two patients showed a tumor shrinkage of more than 20 percent.

"Beyond this impressive preliminary efficacy is that a maximum tolerated dose has still not been reached, suggesting data could further improve from here," Kozul said, calling the results "unparalleled".

The company said 62 percent of the patients showed treatment-related adverse events such as fatigue, nausea, diarrhea, muscle spasms and anemia.

Clovis also released initial results of an early-stage study of its experimental ovarian cancer drug, rucaparib, which showed the disease, at worst, remaining stable in eight out of nine patients, following 12 weeks of treatment.

The disease control rate in seven patients with a mutation in the BRCA gene was 100 percent. Women with a BRCA gene mutation are known to be at a higher risk of developing breast and ovarian cancer.

(Reporting by Pallavi Ail in Bangalore; Editing by Roshni Menon)